title: Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
abstract: Adalimumab belongs to the group of tumour necrosis factor-alpha inhibitors and has been approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse reaction to adalimumab in a 25-year-old female patient. One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. In severe cardiogenic shock, the patient required an extracorporeal membrane-oxygenation system for 8 days until cardiac recovery.
authors.affiliation: Department of Cardiovascular Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. maximilian_emmert@web.de
authors.forename: Maximilian Y
authors.initials: MY
authors.lastname: Emmert
authors.forename: Sacha P
authors.initials: SP
authors.lastname: Salzberg
authors.forename: Lorenz S
authors.initials: LS
authors.lastname: Emmert
authors.forename: Sohil
authors.initials: S
authors.lastname: Behjati
authors.forename: Andre
authors.initials: A
authors.lastname: Plass
authors.forename: Christian
authors.initials: C
authors.lastname: Felix
authors.forename: Volkmar
authors.initials: V
authors.lastname: Falk
authors.forename: Juerg
authors.initials: J
authors.lastname: Gruenenfelder
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000628:therapy; D003424:Crohn Disease / Q000188:drug therapy*; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab